- Hepatitis C Viral Kinetics as a Determinant of Stopping Pegylated Interferon and Ribavirin in Genotype 1 Infection
-
Kim DY
- KMID: 1792354
- Gut Liver.
- 2014 Jul;8(4):335-336.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Combination of Pegylated Interferon and Nucleos(t)ide Therapy: Toward a Cure of Hepatitis B Virus Infection?
-
Cho EJ, Lee JH, Yoon JH
- KMID: 2412034
- Gut Liver.
- 2016 Jul;10(4):497-498.
- doi: 10.5009/gnl15307
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Oromucosal Cytokine Therapy: Mechanism(s) of Action
-
Tovey MG
- KMID: 1123161
- Korean J Hepatol.
- 2002 Jun;8(2):125-131.
Oromucosal cytokine therapy allows large amounts of cytokines to be administered with improved outcome and without dose limiting toxicity. Orally administered cytokines exert their effects by a novel two pronged... -
- CITED
-
- Close
- SHARE
-
- Close
- Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus
-
Tamai H, Ida Y, Kawashima , Shingaki N, Shimizu R, Moribata K, Nasu T, Maekita T, Iguchi M, Kato J, Nakao T, Kitano M
- KMID: 2412236
- Gut Liver.
- 2017 Jul;11(4):551-558.
- doi: 10.5009/gnl16525
BACKGROUND/AIMS: The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such... -
- CITED
-
- Close
- SHARE
-
- Close
- Prediction of a Null Response to Pegylated Interferon alpha-2b Plus Ribavirin in Patients with High Viral Load Genotype 1b Hepatitis C
-
Wada Y, Tamai H, Kawashima , Shingaki N, Mori Y, Kawaguchi , Moribata K, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M
- KMID: 1792366
- Gut Liver.
- 2014 Jul;8(4):421-427.
BACKGROUND/AIMS: The present study aimed to clarify whether virological response within 2 weeks after therapy initiation can predict a null response to pegylated interferon alpha-2b plus ribavirin therapy in patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus
-
Tamai H, Shingaki N, Mori Y, Moribata K, Kawashima , Maeda Y, Niwa T, Deguchi H, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M
- KMID: 2412052
- Gut Liver.
- 2016 Jul;10(4):617-623.
- doi: 10.5009/gnl15193
BACKGROUND/AIMS: This study aimed to predict sustained viral response (SVR) to low-dose pegylated interferon (PEG-IFN) plus ribavirin of elderly and/or cirrhotic patients with genotype 2 hepatitis C virus (HCV) using... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
-
Jung CH, Um SH, Kim TH, Yim SY, Suh SJ, Yim HJ, Seo YS, Choi HS, Chun HJ
- KMID: 2412080
- Gut Liver.
- 2016 Sep;10(5):808-817.
- doi: 10.5009/gnl15360
BACKGROUND/AIMS: Peginterferon plus ribavirin remains a standard therapy for patients with chronic hepatitis C (CHC) in Korea. We investigated the efficacy and long-term outcome of peginterferon and ribavirin therapy in... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study
-
Shin SR, Kim YS, Lim YS, Lee JS, Lee JW, Kim SM, Jeong SH, Sohn JH, Lee MS, Park SH
- KMID: 2412194
- Gut Liver.
- 2017 Mar;11(2):270-275.
- doi: 10.5009/gnl16163
BACKGROUND/AIMS: Because of the limited geographic distribution, there have been insufficient data regarding hepatitis C virus (HCV) genotype 6 in Korea. This study aimed to investigate the clinical characteristics and... -
- CITED
-
- Close
- SHARE
-
- Close
